Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Bladder transitional cell carcinoma? 42 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Bladder transitional cell carcinoma have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.0% of all adverse event reports for LENALIDOMIDE.

42
Reports of Bladder transitional cell carcinoma with LENALIDOMIDE
0.0%
of all LENALIDOMIDE reports
4
Deaths
22
Hospitalizations

How Dangerous Is Bladder transitional cell carcinoma From LENALIDOMIDE?

Of the 42 reports, 4 (9.5%) resulted in death, 22 (52.4%) required hospitalization.

Is Bladder transitional cell carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 42 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Bladder transitional cell carcinoma?

PIOGLITAZONE (398) ADALIMUMAB (96) METHOTREXATE (95) RITUXIMAB (74) TOCILIZUMAB (68) INFLIXIMAB (63) SULFASALAZINE (55) HYDROXYCHLOROQUINE (50) PREDNISONE (48) RANITIDINE (41)

Which LENALIDOMIDE Alternatives Have Lower Bladder transitional cell carcinoma Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Bladder transitional cell carcinoma Reports All Drugs Causing Bladder transitional cell carcinoma LENALIDOMIDE Demographics